Related Experiment Video
Updated: Apr 29, 2026
06:59
The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
Published on: February 27, 2026
165
[Thrombin generation assays and their clinical application]
Anita Kern1, Katalin Várnai2, Barna Vásárhelyi2
1Semmelweis Egyetem, Általános Orvostudományi Kar Laboratóriumi Medicina Intézet Budapest Baross u. 48-52. 1047 Diagon Kft. Budapest.
Orvosi Hetilap
|May 27, 2014
Summary
The thrombin generation test assesses thrombin, a key coagulation enzyme. This global haemostasis assay aids in characterizing thrombosis and bleeding risks, and monitoring anticoagulant and hemophilia treatments.
Area of Science:
- Biochemistry
- Hematology
Context:
- Thrombin is a central enzyme in hemostasis, regulating both pro-coagulant and anti-coagulant processes.
- Assessing thrombin generation is crucial for understanding coagulation dynamics.
Purpose:
- To highlight the utility of the thrombin generation test (TGT) as a global hemostasis assay.
- To demonstrate TGT's applicability in assessing thrombosis risk, monitoring anticoagulant therapies, and evaluating bleeding severity in hemophilia.
Summary:
- The thrombin generation test measures the activity of thrombin, a critical enzyme in blood coagulation.
- It is sensitive to both pro- and anticoagulant factors, making it valuable for risk assessment of thrombosis and bleeding.
- Clinical studies show elevated thrombin generation in patients at high risk for venous or arterial thrombosis.
- TGT can monitor anticoagulant therapies, including novel oral anticoagulants.
- In hemophilia, TGT reflects bleeding severity and is useful for monitoring treatment, including inhibitor-bypassing therapy.
Impact:
- Provides a comprehensive assessment of hemostasis, aiding in the diagnosis and management of bleeding and thrombotic disorders.
- Offers a tool for personalized medicine by monitoring treatment efficacy and guiding therapeutic adjustments.
- Highlights the need for standardization of TGT methods and establishment of cutoff values for widespread clinical adoption.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
01:29Venous Thrombosis III: Interprofessional Care
482
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
467
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
467
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
01:16Clot Retraction and Fibrinolysis
6.0K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.0K
01:20Extrinsic and Intrinsic Pathways of Hemostasis
10.8K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
10.8K